Brainsway is now meeting with the FDA to approve its clinical strategy. The company hopes to receive FDA approval and CE approval at the same time, enabling the company to begin sales in both Europe and the United States in 2008 or 2009. The company's goal is to start by targeting depression, and then move to other areas of mental health.